Subscribe Facebook Twitter Instagram
Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

ADCETRIS- brentuximab vedotin injection, powder, lyophilized, for solution


Patient Information

Peripheral Neuropathy

Advise patients that ADCETRIS can cause a peripheral neuropathy. They should be advised to report to their health care provider any numbness or tingling of the hands or feet or any muscle weakness[seeWarnings and Precautions (5.1)].

Fever/Neutropenia

Advise patients to contact their health care provider if a fever of 100.5 F or greater or other evidence of potential infection such as chills, cough, or pain on urination develops[seeWarnings and Precautions (5.3)].

Infusion Reactions

Advise patients to contact their health care provider if they experience signs and symptoms of infusion reactions including fever, chills, rash, or breathing problems within 24 hours of infusion[seeWarnings and Precautions (5.2)].

Hepatotoxicity

Advise patients to report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice[seeWarnings and Precautions (5.8)].

Progressive Multifocal Leukoencephalopathy

Instruct patients receiving ADCETRIS to immediately report if they have any of the following neurological, cognitive, or behavioral signs and symptoms or if anyone close to them notices these signs and symptoms[seeBoxed Warning,Warnings and Precautions (5.9)]:

changes in mood or usual behavior
confusion, thinking problems, loss of memory
changes in vision, speech, or walking
decreased strength or weakness on one side of the body

Pulmonary Toxicity

Instruct patients to report symptoms that may indicate pulmonary toxicity, including cough or shortness of breath[seeWarnings and Precautions (5.10)].

Acute Pancreatitis

Advise patients to contact their health care provider if they develop severe abdominal pain[seeWarnings and Precautions (5.12)].

Gastrointestinal Complications

Advise patients to contact their health care provider if they develop severe abdominal pain, chills, fever, nausea, vomiting, or diarrhea[seeWarnings and Precautions (5.12)].

Hyperglycemia

Educate patients about the risk of hyperglycemia and how to recognize associated symptoms[seeWarnings and Precautions (5.13)].

Females and Males of Reproductive Potential

ADCETRIS can cause fetal harm. Advise women receiving ADCETRIS to avoid pregnancy during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS.

Advise males with female sexual partners of reproductive potential to use effective contraception during ADCETRIS treatment and for at least 6 months after the final dose of ADCETRIS[seeUse in Specific Populations (8.3)].

Advise patients to report pregnancy immediately[seeWarnings and Precautions (5.14)].

Lactation

Advise patients to avoid breastfeeding while receiving ADCETRIS[seeUse in Specific Populations (8.2)].

Seattle Genetics

Manufactured by:
Seattle Genetics, Inc.
Bothell, WA 98021
1-855-473-2436
U.S. License 1853

ADCETRIS, Seattle Genetics andTrademark Logoare US registered trademarks of Seattle Genetics, Inc.
2019 Seattle Genetics, Inc., Bothell, WA 98021. All rights reserved.



Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources | Sitemap
2017 © Copyright PharmacyHQ.com. Questions?
Please contact: phq.contact@gmail.com